The ULTIMATE I & II Phase 3 trials both have met their primary endpoint with ublituximab treatment demonstrating a statistically significant reduction in annualized relapse rate (ARR) over a 96-week period (p
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
On 6ix: 6ix.com/news/tg-therapeutics-announces-data-presentations-from-the-ultimate-i-ii-phase-3-trials-of
Watch TG Therapeutics' latest callTG Therapeutics (NASDAQ:TGTX) Q2 2026 Earnings Call · Replay · Aug 3Read the transcript of TG Therapeutics (NASDAQ:TGTX) Q2 2026 Earnings CallTG Therapeutics' next earnings callTG Therapeutics (NASDAQ:TGTX) Q3 2026 Earnings Call · Nov 9, 2026 at 8:30 AM ESTRegister
Story so far
- TG Therapeutics Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
- TG Therapeutics Recaps Schedule of Upcoming Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
- TG Therapeutics Announces Data Presentations at the Upcoming XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
Earlier from TG Therapeutics
- TG Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
- TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis of UKONIQ® (umbralisib) in Blood Advances
- TG Therapeutics Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
- TG Therapeutics Recaps Schedule of Upcoming Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
- TG Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Later from TG Therapeutics
- TG Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis
- TG Therapeutics to Host Conference Call on Third Quarter 2021 Financial Results and Business Update
- TG Therapeutics Highlights Data Selected for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting
- TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
- TG Therapeutics to Participate in the B. Riley Securities Fall 2021 Growth Biotech Best Ideas Virtual Series
Follow TG Therapeutics into a list and get an email when it puts out news.
Follow TG Therapeutics